Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

The Nobel Prize in medicine was awarded to Victor Ambros, PhD, of the University of Massachusetts, and Gary Ruvkun, PhD, of ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

HCC accounts for 90% of all liver cancer cases ... NICE has backed the drug after rejecting it earlier this year due to an “improved commercial arrangement” with Sanofi – in other words ...

Recursion has partnered with several healthcare giants, such as Bayer (BAYZF) and Sanofi (SNY ... to royalties for its oncology programs. Additionally, Recursion is planning to merge with Exscientia ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment ... along with GlaxoSmithKline’s Nucala and Teva’s Cinqaero. These drugs inhibit interleukin (IL)-5, while Dupixent inhibits ...

Innovent Biologics (HKEX: 01801) has formed a strategic partnership with ASK Pharm (SZ: 002755) to commercialize limertinib, ...

MIT study reveals 5-fluorouracil functions by disrupting RNA, not DNA, potentially impacting cancer treatment.

Potential new benefit for home health care for seniors to be funded through Medicare drug price negotiations, likely ...